Print

AVIVA Biosciences Corporation Launches Electrophysiology On Demand Discovery Service (EPOD), Providing Companies The Highest Automated Electrophysiology Capacity In The Drug Discovery Service Industry  
4/25/2006 12:55:54 PM

SAN DIEGO, April 25 /PRNewswire/ -- AVIVA Biosciences Corporation announces the launch of its Electrophysiology on Demand (EPOD) service using an expanded bank of PatchXpress(TM) automated electrophysiology instruments. EPOD encompasses all necessary activities for drug discovery targeted or associated with ion channels. "We have built a specialized group combining state of the art equipment, personnel and skills that will allow our customers to go from the validation of a target ion channel cell line to the screening for drug candidates," said Dr. Andrea Ghetti, Senior Director of the Pharma Services division.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030428/AVIVALOG0 )

EPOD services were first introduced to a select group of clients at the recent Society of Toxicology AVIVA workshop March 4th in San Diego where numerous industry experts spoke on the topic of "The Path to Cardiac Friendly Drugs," including Dr. Heather Guthrie of Roche Pharmaceuticals. Workshop attendees included representatives from Johnson & Johnson, Novartis and other industry leading organizations. This workshop is planned as an annual event that will focus on issues surrounding ion channels and drug discovery. EPOD services are now available to the industry at large.

EPOD incorporates all molecular biology support activities related to drug discovery for ion channels, including novel cell lines, custom clones, and cell line maintenance along with the advantage of automated electrophysiology. AVIVA has added Dr. Victor Panchenko, formerly of Vertex drug discovery, to be the technical lead for the EPOD services and he commented "EPOD represents the best of both worlds, high throughput ion channel drug discovery program without the overwhelming time and financial burden."

Based In San Diego, California AVIVA Biosciences Corporation develops enabling drug discovery and diagnostic technologies by integrating cell biology and chemistry into biochips. AVIVA Biosciences products combine unique surface chemistry with advanced design to address into multiple applications, dedicated primarily to automation and improved productivity of cell-based research and new diagnostic procedures. AVIVA currently manufactures the disposable 16 channel version of SealChip(TM) exclusively for the automated electrophysiology instrument, PatchXpress(TM) and also offers other ion channel related services to drug discovery and development companies.

Photo: http://www.newscom.com/cgi-bin/prnh/20030428/AVIVALOG0AP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comAVIVA Biosciences Corporation

CONTACT: Andrea Ghetti, Sr. Director Pharma Services, AVIVA BiosciencesCorporation, +1-858-552-0888, Press2006@avivabio.com


//-->